NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Varun Ektare
Pharmerit International - Rotterdam / Netherlands
Others
AD Scientific Index ID: 5452332
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Varun Ektare's MOST POPULAR ARTICLES
1-)
Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care settingV Ektare, A Khachatryan, M Xue, M Dunne, K Johnson, J StephensJournal of Medical Economics 18 (12), 1092-1101, 2015622015
2-)
Does biosimilar bevacizumab offer affordable treatment options for cancer patients in the USA? A budget impact analysis from US commercial and Medicare payer perspectivesJ Yang, R Liu, V Ektare, J Stephens, A ShelbayaApplied Health Economics and Health Policy 19, 605-618, 2021232021
3-)
Post-gemcitabine therapy for patients with advanced pancreatic cancer–A comparative review of randomized trials evaluating oxaliplatin-and/or irinotecan-containing regimensA Vogel, F Ciardiello, RA Hubner, JF Blanc, A Carrato, Y Yang, DA Patel, ...Cancer Treatment Reviews 50, 142-147, 2016222016
4-)
Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitusJMS Lopez, B Macomson, V Ektare, D Patel, M BottemanAmerican Health & Drug Benefits 8 (6), 309, 2015192015
5-)
Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitusVU Ektare, JM Lopez, SC Martin, DA Patel, MF Rupnow, MF BottemanAm J Manag Care 20 (10 Suppl), S204-15, 2014122014
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept